Scientists trace severe COVID-19 to faulty genes and an autoimmune condition
In both groups, the upshot is basically the same: The patients lack type I interferon, a set of 17 proteins crucial for protecting cells and the body from viruses.
Research & Development News
Johns Hopkins researchers publish COVID-19 'prediction model'
Web resources bring new insight into COVID-19
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX facility
64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines reach those in greatest need, whoever they are and wherever they live. These 64 economies include commitments from 35 economies as well as the European Commission which will procure doses on behalf of 27 EU member states plus Norway and Iceland. Researchers uncover early results about an existing tuberculosis vaccine that has been hypothesized to help against the coronavirus
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
Designed antiviral proteins inhibit SARS-CoV-2 in the lab
In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.
More Pharma News ...
Business & Industry
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
- Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints
- Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study
Research & Development
- Doctors use existing treatment earlier to save the lives of COVID-19 patients
- European Commission approves contract with Moderna to ensure access to a potential vaccine
- New therapy for flu may help in fight against COVID-19
- The drug aprotinin inhibits entry of SARS-CoV2 in host cells
- Chinese vaccine candidate based on inactivated SARS-CoV-2 virus appears safe and induces an immune response in healthy volunteers
- Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response
- Immunological memory after cured Sars-CoV-2 infection
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- FDA authorizes monoclonal antibodies for treatment of COVID-19
- FDA approves first treatment for COVID-19
- Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation
- FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment